References
- Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221–234.
- Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245–1246.
- Manning AL, Dyson NJ. RB: mitotic implications of a tumour suppressor. Nat Rev Cancer 2012;12:220–226.
- Hoechtlen-Vollmar W, Menzel G, Bartl R, et al. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000;109:30–38.
- Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001;67:296–301.
- Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345–11353.
- Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98:217–223.
- Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008;18:528–535.
- Kryukov F, Dementyeva E, Kubiczkova L, et al. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics 2013;102:243–249.
- Xiao Z, Chen Z, Gunasekera AH, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003;278:21767–21773.
- Kishimoto T, Okumura E. In vivo regulation of the entry into M-phase: initial activation and nuclear translocation of cyclin B/Cdc2. Prog Cell Cycle Res 1997;3:241–249.
- Krämer A, Schultheis B, Bergmann J, et al. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 2002;16:1844–1851.
- Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007;109:1228–1232.
- Juge-Morineau N, Mellerin MP, Francois S, et al. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995; 91:664–667.
- Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Anticancer Res 2000;20: 4619–4625.